[go: up one dir, main page]

AU2002322066A1 - N-terminally truncated galectin-3 and antibodies for treating cancer - Google Patents

N-terminally truncated galectin-3 and antibodies for treating cancer

Info

Publication number
AU2002322066A1
AU2002322066A1 AU2002322066A AU2002322066A AU2002322066A1 AU 2002322066 A1 AU2002322066 A1 AU 2002322066A1 AU 2002322066 A AU2002322066 A AU 2002322066A AU 2002322066 A AU2002322066 A AU 2002322066A AU 2002322066 A1 AU2002322066 A1 AU 2002322066A1
Authority
AU
Australia
Prior art keywords
antibodies
treating cancer
terminally truncated
truncated galectin
galectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002322066A
Inventor
Gary A. Jarvis
Constance M. John
Hakon Leffler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MANDALMED Inc
Original Assignee
MANDALMED Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MANDALMED Inc filed Critical MANDALMED Inc
Publication of AU2002322066A1 publication Critical patent/AU2002322066A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002322066A 2001-06-08 2002-06-10 N-terminally truncated galectin-3 and antibodies for treating cancer Abandoned AU2002322066A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29697001P 2001-06-08 2001-06-08
US60/296,970 2001-06-08
PCT/US2002/018478 WO2002100343A2 (en) 2001-06-08 2002-06-10 N-terminally truncated galectin-3 and antibodies for treating cancer

Publications (1)

Publication Number Publication Date
AU2002322066A1 true AU2002322066A1 (en) 2002-12-23

Family

ID=23144316

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002322066A Abandoned AU2002322066A1 (en) 2001-06-08 2002-06-10 N-terminally truncated galectin-3 and antibodies for treating cancer

Country Status (4)

Country Link
EP (1) EP1534317A4 (en)
AU (1) AU2002322066A1 (en)
CA (1) CA2488850A1 (en)
WO (1) WO2002100343A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
KR101025143B1 (en) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 Hydrolytically Stable Maleimide-terminated Polymers
AU2004229399B2 (en) 2003-04-07 2010-08-05 Prospect Therapeutics, Inc. Composition and uses of galectin antagonists
CA2742265C (en) * 2008-10-29 2014-07-15 Bg Medicine, Inc. Galectin-3 immunoassay
CN102488619B (en) 2011-12-05 2014-08-06 上海交通大学 Device for continuously producing exenatide microspheres and method for controlling release rate of microspheres
JP2016507503A (en) 2012-12-20 2016-03-10 ヘンリー フォード ヘルス システム Method for treating diastolic heart failure by inhibiting galectin-3
US12390486B2 (en) 2012-12-20 2025-08-19 Henry Ford Health System Method for treating diastolic heart failure by inhibiting galectin-3
US20150157691A1 (en) * 2013-12-05 2015-06-11 Texas Tech University System Galectin-3 to Treat Ovarian Cancer
US20150216931A1 (en) * 2014-02-03 2015-08-06 Texas Tech University System Galectin-3 inhibitor (gal-3m) is associated with additive anti-myeloma and anti-solid tumor effects, decreased osteoclastogenesis and organ protection when used in combination with proteasome inhibitors
EP3188716B1 (en) 2014-09-03 2022-10-26 GeneSegues, Inc. Therapeutic nanoparticles and related compositions, methods and systems

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0218700A4 (en) * 1985-04-23 1988-09-19 Medical Biology Inst DETERMINATION OF AN IGE BINDING PROTEIN BY MOLECULAR CLONING.
US20020019009A1 (en) * 1999-12-09 2002-02-14 Roggen Erwin Ludo High throughput screening (HTS) assays
AU2001243622A1 (en) * 2000-03-13 2001-09-24 La Jolla Institute For Allergy And Immunology Monocyte chemoattractant activity of galectin-3

Also Published As

Publication number Publication date
CA2488850A1 (en) 2002-12-19
EP1534317A4 (en) 2005-10-12
EP1534317A2 (en) 2005-06-01
WO2002100343A2 (en) 2002-12-19
WO2002100343A3 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
AUPR395801A0 (en) Antibodies against cancer
AU2002338015A1 (en) Human CDR-grafted antibodies and antibody fragments thereof
IL200404A (en) Conjugates of antibodies that bind 191p4d12(b)proteins and uses thereof for treating cancer
AU2003224076A1 (en) Antibody combination useful for tumor therapy
AU2002305478A1 (en) Conjugates of reduced antibodies and biomolecules
AU2002364708A1 (en) Novel compositions and methods for cancer
AU2001290860A1 (en) Spas-1 cancer antigen
AU2002349543A1 (en) Tumor antigens
AU2002351374A1 (en) Antibodies to treat cancer
AU2002322066A1 (en) N-terminally truncated galectin-3 and antibodies for treating cancer
AU2002315066A1 (en) Methods for making antibody fragments and compositions resulting therefrom
AU2002308642A1 (en) Methods for treating cancer
AU2001257325A1 (en) Cancer treatment
AU2002337943A1 (en) Novel compositions and methods for cancer
AU2002337713A1 (en) Pharmaceutical compositions and methods for treating cancer
AU2002360815A1 (en) Human breast cancer biomarkers
AU2002305138A1 (en) Methods and materials for cancer treatment
AU5632500A (en) Cancer associated antigens and uses therefor
AU2002363807A1 (en) Breast cancer associated polypeptide
AU2002366364A1 (en) E2f and cancer therapy
AU2002351382A1 (en) Combination cancer therapy
AU2002360454A1 (en) Methods and compositions for treating cancer
AU2001257168A1 (en) Cancer treatment
AUPR589001A0 (en) An antibody cancer therapeutic
AU2002356097A1 (en) Hydrazinopeptoids and their uses for treating cancers

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase